Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

Financial Penalties Scope Widened Under New EU Regulation

A new EU regulation due to come into effect later this month will amend the rules on the centralized procedure.

Regulation Europe

Singapore Reveals Phase-In Plans For eCTD

The Health Sciences Authority will seek industry’s feedback on the plans it has for introducing in Singapore the electronic format of the common technical document that drug companies use to make their regulatory submission.

Regulation Singapore

NZ To Replace 'Outdated And Piecemeal' Device Rules

There are significant changes in store for New Zealand’s medical device sector, including a new regulator and a set of pre- and post-market regulatory controls.

New Zealand Policy & Regulation

Australia Consults On Which EU Definitions To Align With And Which To Ignore

Australia's Therapeutic Goods Administration also wants to extend the scope of the products it regulates as medical devices to include the non-medical-use products now captured in the new EU Medical Device Regulation.

Australia Compliance

Regulators Seek Comments On UDI For Australia

The Therapeutic Goods Administration wants to introduce a unique device identification (UDI) system in Australia and align its implementation with the transitional arrangements for a similar system in the EU.

Policy & Regulation Medical Device

New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit

The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit. 
Europe United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register